WO2025126049 - MULTIPLEX GENE EDITING
National phase entry is expected:
Publication Number
WO/2025/126049
Publication Date
19.06.2025
International Application No.
PCT/IB2024/062469
International Filing Date
11.12.2024
Title **
[English]
MULTIPLEX GENE EDITING
[French]
ÉDITION GÉNÉTIQUE MULTIPLEX
Applicants **
CRISPR THERAPEUTICS AG
Inventors
KULMAN, John
FERULLO, Daniel
FOCHTMAN, Brian
VISHWANATHAN, Aishwarya
ACHUTHAN, Vasudevan
Priority Data
63/608,807
11.12.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4056 | |
| EPO | Filing, Examination, Granting | 29875 | |
| Japan | Filing, Examination, Granting | 3236 | |
| South Korea | Filing, Examination, Granting | 4272 | |
| USA | Filing, Examination, Granting | 11640 |
Total:
53,079
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides methods of making multiplex targeted gene edits by introducing to DNA molecules or a cell comprising DNA molecules two or more guide RNAs. In some embodiments, the present disclosure provides base editing fusion proteins, protein complexes, compositions, cells and methods of using the same for targeted nucleic acid editing. The base editing fusion protein can comprise a Cas9 domain and a deaminase domain capable of deaminating a nucleotide base in a target nucleic acid sequence.[French]
La présente divulgation concerne des procédés de fabrication d'éditions de gènes ciblés multiplex par introduction, dans des molécules d'ADN ou une cellule comprenant des molécules d'ADN, d'au moins deux ARN guides. Dans des modes de réalisation, la présente divulgation concerne des protéines de fusion d'édition de base, des complexes de protéines, des compositions, des cellules et des procédés d'utilisation associées pour l'édition ciblée d'acides nucléiques. La protéine de fusion d'édition de base peut comprendre un domaine Cas9 et un domaine désaminase pouvant désaminer une base nucléotidique dans une séquence d'acide nucléique cible.